APLS - Apellis Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

APLS is currently covered by 20 analysts with an average price target of $31.57. This is a potential upside of $13.9 (78.66%) from yesterday's end of day stock price of $17.67.

Apellis Pharmaceuticals's activity chart (see below) currently has 222 price targets and 282 ratings on display. The stock rating distribution of APLS is 63.45% BUY and 36.55% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 61.38% with an average time for these price targets to be met of 185.96 days.

Highest price target for APLS is $82, Lowest price target is $18, average price target is $42.47.

Most recent stock forecast was given by GRAIG SUVANNAVEJH from MIZUHO on 14-May-2025. First documented stock forecast 04-Dec-2017.

Currently out of the existing stock ratings of APLS, 92 are a BUY (63.45%), 53 are a HOLD (36.55%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$20

$2.55 (14.61%)

$30

5 days ago
(14-May-2025)

4/11 (36.36%)

$3.3 (19.76%)

59

Buy

$52

$34.55 (197.99%)

$106

10 days ago
(09-May-2025)

2/17 (11.76%)

$34.7 (200.58%)

570

Buy

$23

$5.55 (31.81%)

$47

10 days ago
(09-May-2025)

3/9 (33.33%)

$5.7 (32.95%)

12

Hold

$20

$2.55 (14.61%)

$31

11 days ago
(08-May-2025)

2/4 (50%)

$2.19 (12.30%)

32

Hold

$18

$0.55 (3.15%)

$21

11 days ago
(08-May-2025)

5/7 (71.43%)

$0.19 (1.07%)

42

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is APLS (Apellis Pharmaceuticals) average time for price targets to be met?

On average it took 185.96 days on average for the stock forecasts to be realized with a an average price target met ratio 61.38

Which analyst has the current highest performing score on APLS (Apellis Pharmaceuticals) with a proven track record?

STEVEN SEEDHOUSE

Which analyst has the most public recommendations on APLS (Apellis Pharmaceuticals)?

Steven Seedhouse works at RAYMOND JAMES and has 6 price targets and 4 ratings on APLS

Which analyst is the currently most bullish on APLS (Apellis Pharmaceuticals)?

Madhu Kumar with highest potential upside - $123.55

Which analyst is the currently most reserved on APLS (Apellis Pharmaceuticals)?

Dae Gon Ha with lowest potential downside - -$0

Apellis Pharmaceuticals in the News

Apellis Pharmaceuticals' Funding Gaps, Weak Syfovre Sales Cloud Outlook, BofA Says

Apellis Pharmaceuticals (APLS) has had a difficult Q1 as charitable foundation funding gaps and weak PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in

Apellis price target lowered to $20 from $28 at Scotiabank

Scotiabank analyst Greg Harrison lowered the firm’s price target on Apellis (APLS) to $20 from $28 and keeps a Sector Perform rating on the shares. The company had a weak Q1, with Syfovre revenues in geographic atrophy missing expectations due to underfunding of retinal therapeutics co-pay assistance programs and inventory draw down, the analyst tells...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?